How many investments has Brace Pharma made?

Brace Pharma has 15 tracked investments.

What stage does Brace Pharma invest at?

Brace Pharma invests at the Late Stage stage.

What sectors does Brace Pharma focus on?

Brace Pharma focuses on Biotech, Medical Devices.

Where is Brace Pharma located?

Brace Pharma is headquartered in Atlanta, US.

Who does Brace Pharma co-invest with?

Brace Pharma most often shares deals with F-Prime Capital Partners, age1, Aisling Capital, among 34 tracked co-investors.

Brace Pharma

Venture capital

Atlanta · Late Stage · 3 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Brace Pharma Capital invests in innovative therapies targeting diseases characterized by a high degree of unmet medical need and insufficient existing treatment options. The firm seeks to back companies developing life-changing medicines and invites prospective candidate investment companies to reach out for consideration.

Invests inBiotech Medical Devices Atlanta Brazil

Source: firm website, verified Aug 3, 2026.

Stage

Late Stage

Atlanta, US

Instruments

Equity

Tracked investments

Team · 3 people

from the firm's website

Daniel E. Salazar· Vice President of Clinical & Regulatory

Salazar leads clinical and regulatory work at Brace Pharma Capital and is Chief Scientific Officer and board member at EMS S/A. He has over 25 years in drug discovery and development, contributing to 40+ IND filings and 9 NDAs, and is an adjunct associate professor at the University of Florida. He previously held a senior translational medicine role at Otsuka Pharmaceutical Development.

Racheal Smith· Executive Assistant & Office Manager

Smith is an executive assistant and office manager at Brace Pharma Capital with experience in business operations across the medical, travel, and banking industries. She holds a master's degree in business management from Salem International University.

Todd Brady· Director of Finance & Investments

Brady leads finance and investments at Brace Pharma Capital and serves as a director for portfolio companies including GeNO, Avidity Biosciences, and Tyrogenex. He has a background across equity research, asset management, private equity, and corporate banking, holds an MBA from Schulich School of Business, and is a CFA charterholder.

What they invest in

from 12 of 15 portfolio companies

Biotech ×12Healthtech ×6Medical Devices ×4Deep Tech ×2Digital Health ×1FemTech ×1Longevity ×1

HQs:United States×9

Investments · 15 tracked

founders shown can be your intro path

miRagen TherapeuticsNASDAQ: VRDN

Discovers and develops microRNA-targeting therapies for areas of high unmet medical need.

BiotechBoulder, US

William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)David Rodman(Executive Officer)Christopher J Morl(Executive Officer)Christopher Bowden(Director)Paul D. Rubin(Executive Officer)

Co-investorsMC Healthcare Ventures Boulder Ventures

Precision BioSciencesprecisionbiosciences.com in 𝕏NASDAQ: DTIL

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)Derek Jantz(Co-founder)TODD MELBY(Executive Officer)

Co-investorsage1 Aliment Capital F-Prime Capital Partners OCV Partners OUP (Osage University Partners)Pontifax AgTech +4 more

Zymeworkszymeworks.com in 𝕏NASDAQ: ZYME

Zymeworks is a royalty-driven biotechnology company that develops multifunctional antibody-based therapeutics, including antibody-drug conjugates and multispecific antibodies, for solid tumors and other difficult-to-treat diseases.

BiotechDigital HealthHealthtechLongevityMedical DevicesVancouver, US

ALI TEHRANI(Executive Officer, Director)GORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)SURJIT DIXIT(Executive Officer)DAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in

Co-investorsCTI Life Sciences Fund L.P.Lumira Ventures Nextech Invest WUTIF Capital

Antiva Biosciencesantivabio.com in

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

Gail Maderis(Director)Kristine Ball(Executive Officer, Director)Elaine Chien(Executive Officer)Sarah Walter(Executive Officer)Raju Gadiraju(Executive Officer)John Sayward(Executive Officer)

Co-investorsAdjuvant Capital Canaan Partners Lumira Ventures MPM BioImpact OUP (Osage University Partners)Sofinnova Ventures +1 more

Avidity Biosciences

BiotechLa Jolla, US

Troy Wilson PhD., JD(Executive Officer, Director)P. Kent Hawryluk(Executive Officer)Mark E. Davis(Director)Frank McCormick(Director)Troy Wilson(Executive Officer, Director)

BoardTodd Brady(Director)

Co-investorsFrazier Life Sciences

Avidity Nanomedicinesaviditybiosciences.com in

Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.

BiotechDeep TechHealthtechMedical Devices

Co-investorsAvoro Capital Advisors F-Prime Capital Partners Frazier Life Sciences Moore Venture Partners

Avrobioavrobio.com

Co-investorsAisling Capital

F2Gf2g.com

F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations.

BiotechHealthtech

Co-investorsAdvent Life Sciences Aisling Capital AMR Action Fund Astellas Venture Management LLC Sofinnova Partners Sunstone Capital +3 more

GeNO LLC

Gliknikgliknik.com

Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.

BiotechBaltimore, US

David S. Block(Executive Officer, Director)Elizabeth C. Block(Executive Officer)Raymond Shinazi(Director)Joseph Klein(Director)Elizabeth Block(Executive Officer)Mark Lerner(Director)

Co-investorsFirst In Ventures

Navitor Pharmaceuticalsnavitorpharma.com

BiotechCambridge, US

Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)George Vlasuk(Executive Officer, Director)

BoardJean-Francois Formela(Director)inAlan Crane(Director)Marian Nakada(Director)

Co-investorsage1 Sanofi Ventures Atlas Venture Polaris Partners SR One Capital Management

ReViralreviral.co.uk

Co-investorsAndera Partners

Turnstone Biologicsturnstonebio.com

BiotechNew York, US

Michael Burgess(Executive Officer)Jose Manuel Otero(Executive Officer)Robert Gould(Director)Jane Henderson(Executive Officer)Stefan Larson(Director)Patrick Machado(Director)

Co-investorsF-Prime Capital Partners FACIT (Fight Against Cancer Innovation Trust)Foothill Ventures Venture Ontario OrbiMed Versant Ventures

TyrogenexFeb 2016

BiotechPalm Beach Gardens, US

Michael Webb(Executive Officer, Director)Joseph Straight(Executive Officer)Chris Liang(Executive Officer, Director)Sheridan G. Snyder(Executive Officer, Director)Dennis L. Palmgren(Director)Sheridan D. Snyder(Executive Officer)

VERO Biotechvero-biotech.com in

VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings.

BiotechHealthtechMedical Devices

Co-investorsRunway Growth Capital

Exits · 3

IPOs and acquisitions across the tracked portfolio

miRagen TherapeuticsNASDAQ: VRDNPrecision BioSciencesNASDAQ: DTILZymeworksNASDAQ: ZYME

Portfolio news

latest coverage across their companies

Precision BioSciences Q2 2026 results: Warrant revaluation widens the net loss

Precision BioSciences · tradingkey.com · Aug 6, 2026

Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run

Zymeworks · finance.yahoo.com · Jul 1, 2026

F2G CEO outlines biotech’s FDA resubmission plans, funding and expansion

F2G · endpoints.news · Jan 23, 2026

Frequently asked questions

How many investments has Brace Pharma made?: Brace Pharma has 15 tracked investments.
What stage does Brace Pharma invest at?: Brace Pharma invests at the Late Stage stage.
What sectors does Brace Pharma focus on?: Brace Pharma focuses on Biotech, Medical Devices.
Where is Brace Pharma located?: Brace Pharma is headquartered in Atlanta, US.
Who does Brace Pharma co-invest with?: Brace Pharma most often shares deals with F-Prime Capital Partners, age1, Aisling Capital, among 34 tracked co-investors.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

EDB Investments

EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.

$12M – $400M